论文部分内容阅读
目的:分析浙江地区11家医院肺癌合并糖尿病患者口服降糖药的使用情况,为肺癌合并糖尿病患者此类药物的临床合理应用提供依据。方法:选取浙江地区11家医院肺癌合并糖尿病患者口服降糖药2009~2014年每年40d的医嘱数据,分析口服降糖药的用药金额、用药频度(DDDs)、限定日费用(DDC)和药物利用指数(DUI)等指标。结果:用药金额占前三位药物的分别是阿卡波糖、格列齐特和瑞格列奈;DDDs排前四位是阿卡波糖、二甲双胍、瑞格列奈和格列美脲;DDC排前四位是罗格列酮、西格列汀、格列齐特和阿卡波糖;12种口服降糖药的DUI值介于0.27~2.94。结论:浙江地区11家医院肺癌合并糖尿病患者口服降糖药的使用存在不合理现象,临床用药时应进一步掌握合理用药指征。
OBJECTIVE: To analyze the use of oral hypoglycemic agents in 11 patients with lung cancer and diabetes mellitus in Zhejiang province, and to provide basis for the clinical rational use of these drugs in patients with lung cancer and diabetes mellitus. Methods: The prescription data of oral hypoglycemic agents in 11 patients with lung cancer and diabetes mellitus in Zhejiang province from 2009 to 2014 were analyzed 40 days a year, and the dosage of oral hypoglycemic agents, frequency of DDDs, DDC and drugs Use index (DUI) and other indicators. Results: Acarbose, gliclazide and repaglinide were the most expensive drugs in the first three groups; acarbose, metformin, repaglinide and glimepiride were the top four DDDs in DDDs; The top four DDC rankings were rosiglitazone, sitagliptin, gliclazide and acarbose; DUI values of 12 oral hypoglycemic agents ranged from 0.27 to 2.94. Conclusion: The use of oral hypoglycemic agents in 11 patients with lung cancer and diabetes mellitus in Zhejiang Province is unreasonable. Clinical indications should be further grasped.